Original Article

You have full text access to this OnlineOpen article

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients†‡

  1. Kathryn A. Phillips PhD1,§,*,
  2. Deborah A. Marshall PhD2,
  3. Jennifer S. Haas MD, MSPH3,
  4. Elena B. Elkin PhD4,
  5. Su-Ying Liang PhD1,
  6. Michael J. Hassett MD5,
  7. Ilia Ferrusi BSc6,
  8. Jane E. Brock MBBS, PhD7,
  9. Stephanie L. Van Bebber MSc1

Article first published online: 14 SEP 2009

DOI: 10.1002/cncr.24574

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5166–5174, 15 November 2009

Additional Information

How to Cite

Phillips, K. A., Marshall, D. A., Haas, J. S., Elkin, E. B., Liang, S.-Y., Hassett, M. J., Ferrusi, I., Brock, J. E. and Van Bebber, S. L. (2009), Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer, 115: 5166–5174. doi: 10.1002/cncr.24574

Author Information

  1. 1

    Department of Clinical Pharmacy, University of California-San Francisco, San Francisco, California

  2. 2

    Department of Clinical Epidemiology and Biostatistics, McMaster University, and Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, Ontario, Canada

  3. 3

    Division of General Medicine, Brigham and Women's Hospital, Boston, Massachusetts

  4. 4

    Department of Epidemiology and Biostatistics, Memorial-Sloan Kettering Cancer Center, New York, New York

  5. 5

    Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, Massachusetts

  6. 6

    Department of Clinical Epidemiology and Biostatistics, McMaster University and Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, ON, Canada

  7. 7

    Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts

  1. §

    Fax: (415) 502-0792

*Center for Translational and Policy Research on Personalized Medicine (TRANSPERS Center), Department of Clinical Pharmacy, University of California, San Francisco, 3333 California Street #420, San Francisco, CA 94143-0613

  1. †

    We thank i3 Innovus, Julia Trosman, and the Center for Business Models in Healthcare for their commissioned reports developed for the Department of Clinical Pharmacy at the University of California-San Francisco. We also thank Mr. Kuo Tong, president and founder of Quorum Consulting in San Francisco, California, for the use of results from his poster presentation given at the 2007 Breast Cancer Symposium.

  2. ‡

    Dr. Phillips obtained funding, drafted and revised the manuscript, and provided leadership and supervision in conceptualization and design of the study, acquisition of data, and analysis and interpretation of data. Drs. Liang and Marshall participated in conceptualization and design of the study, acquisition of data, analysis and interpretation of data, supervision, and revisions to the manuscript. Dr. Haas participated in conceptualization and design of the study, analysis and interpretation of the data, and revisions to the manuscript. Drs. Elkin, Hassett, and Brock, and Ms. Van Bebber participated in design of the study, analysis and interpretation of the data, and revisions to the manuscript. Ms Ferrusi participated in design of the study, acquisition of the data, analysis and interpretation of the data, and revisions to the manuscript.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 14 SEP 2009
  3. Manuscript Accepted: 5 FEB 2009
  4. Manuscript Revised: 16 JAN 2009
  5. Manuscript Received: 7 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (161K)

References

  • 1
    Agency for Healthcare Research and Quality. Genetic Tests for Cancer. Available at: http://www.ahrq.gov/clinic/ta/gentests/gentests.pdf#search=%22horizon%20scanning%20genetic%20tests%22. Accessed August 22, 2006.
  • 2
    Bazell R. Her-2 The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. New York: Random House; 1998.
  • 3
    Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003; 16: 173-182.
  • 4
    Phillips KA. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA. 2008; 300: 2542-2544.
  • 5
    Woolf SH. The meaning of translational research and why it matters. JAMA. 2008; 299: 211-213.
  • 6
    Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA. 2005; 294: 1399-1402.
  • 7
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
  • 8
    Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006; 4( suppl 3): S1-S22; quiz S23-24.
  • 9
    Paik S, Kim C, Jeong J. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3p and/or FISH-positive tumors: central testing results from NSABP B-31 [abstract]. J Clin Oncol. 2007 ASCO Annu Meeting Proc. Part I. 2007; 25( 18S): 511.
  • 10
    Garrison LP, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. Cancer. 2007; 110: 489-498.
    Direct Link:
  • 11
    Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25: 625-633.
  • 12
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634-641.
  • 13
    Stark A, Kucera G, Lu M, Claud S, Griggs J. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care. 2004; 16: 517-521.
  • 14
    Tong KB, Chen E, Gregory C, Kim D. HER-2 testing and trastuzumab use in the medicare population (abstract). Paper presented at: Book and abstracts of the 2007 Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract 141.
  • 15
    Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002; 94: 852-854.
  • 16
    Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002; 94: 855-857.
  • 17
    Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005; 23: 4287-4297.
  • 18
    Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006: 153-157.
  • 19
    Renshaw RM. Outcomes-based access: what will it mean for biologics? Biotechnology Healthcare. 2006; June: 39-44. Available at: http://www.biotechnologyhealthcare.com/journal/fulltext/3/3/BH0303039.pdf?CFID=41122935&CFTOKEN=93433706.
  • 20
    Culliton BJ. Insurers and ‘targeted biologics’ for cancer: a conversation with Lee N. Newcomer. Health Aff (Millwood). 2008; 27: w41-w51.
  • 21
    Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22: 854-863.
  • 22
    Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol. 2007; 25( suppl) 6S. Abstract 512.
  • 23
    Allison M. Is personalized medicine finally arriving? Nat Biotechnol. 2008; 26: 509-517.
  • 24
    Billings PR. Three barriers to innovative diagnostics. Nat Biotechnol. 2006; 24: 917-918.
  • 25
    Garrison LP, Jr, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev. 2008; 40: 377-401.
  • 26
    Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007; 9: 665-674.
  • 27
    Teutsch SM, Berger ML, Weinstein MC. Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood). 2005; 24: 128-132.
View Full Article (HTML) Get PDF (161K)